Characteristics, management, and in-hospital mortality of acute myocardial infarction in the "real world" in France - Data from a large unselected cohort of 2,519 consecutive patients in a French region

Acta Cardiologica

Volumn 55, Issue 6, 2000, Pages 357-366

  De Gevigney, Guy ^a   Ecochard, René ^b   Colin, Cyrille ^b   Rabilloud, Muriel ^b   Excoffier, Sylvie ^a   Cao, Danièle ^a   Cheneau, Edouard ^a   Milon, Hugues ^c   Delahaye, François ^a  

^a LOUIS PRADEL HOSPITAL   (France)

^b Dept d'Info Biostatistiques M ^*  (France)

^c CROIX ROUSSE HOSPITAL   (France)

Author keywords

In hospital mortality; Multivariate analysis; Myocardial infarction; Registry; Thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; FEMALE; FIBRINOLYTIC THERAPY; FRANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; Q WAVE; STATISTICAL ANALYSIS;

EID: 0034486392     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.55.6.2005767     Document Type: Article

References (48)

1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
2. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction. Evidence from clinical trials. N Engl J Med 1996; 335: 1660-1667.
3. rd, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). J Am Coll Cardiol 1996; 28: 1328-1428.
4. Danchin N, Vaur L, Genès N, Renaut M, Ferrières J, Etienne S, Cambou JP. Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results. J Am Coll Cardiol 1997; 30: 1598-1605.
5. Rustige J, Schiele R, Burczyk U, Koch A, Gottwik M, Neuhaus KL, Tebbe U, Uebis R, Senges J. The 60 Minutes Myocardial Infarction Project. Treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J 1997; 18: 1438-1446.
6. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD, for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-2114.
7. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
8. Mahon NG, O'Rorke C, Codd MB, McCann HA, McGarry K, Sugrue DD. Hospital mortality of acute myocardial infarction in the thrombolytic era. Heart 1999; 81: 478-482.
9. Ferrières J, Cambou JP, Ruidavets JB, Pous J. Trends in acute myocardial infarction prognosis and treatment in Southwestern France between 1985 and 1990 (The MONICA Project - Toulouse). Am J Cardiol 1995; 75: 1202-1205.
10. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
11. Colin C, Ecochard R, Delahaye F, Landrivon G, Messy P, Morgon E, Matillon Y. Data quality in a DRG-based information system. Int J Qual Health Care 1994; 6: 275-280.
12. SAS software version 6.12, SAS Institute, SAS Campus Drive, Cary, NC, USA.
13. Rouleau JL, Talajic M, Sussex B, Potuin P, Warnica W, Davies RF, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P. Myocardial infarction patients in the 1990s. Their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) study. J Am Coll Cardiol 1996; 27: 1119-1127.
14. Kostis JB, Wilson AC, O'Dowd K, Gregory P, Chelton S, Cosgrove NM, Chirala A, Cui T, for the MIDAS Study Group. Sex differences in the management and long-term outcome of acute myocardial infarction. A statewide study. Myocardial Infarction Data Acquisition system. Circulation 1994; 90: 1715-1730.
15. Vaccarino V, Horwitz RI, Meehan TP, Petrillo MK, Radford MJ, Krumholz HM. Sex differences in mortality after myocardial infarction: evidence for a sex-age interaction. Arch Intern Med 1998; 158: 2054-2062.
16. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999; 341: 217-225.
17. Haas B, Arveiler D, Cambou JP, Amouyel P, Bingham A, Richard JL, Schaffer P. Prise en charge thérapeutique de l'infarctus du myocarde: évolution dans le projet MONICA-France entre 1985 et 1991. Rev Epidémiol Santé Publ 1996; 44: S53-S61.
18. Dellborg M, Eriksson P, Riha M, Swedberg K. Declining hospital mortality in acute myocardial infarction. Eur Heart J 1994; 15: 5-9.
19. Lee KL, Woodlief LH, Topol EJ, Weaver D, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 1995; 91: 1659-1668.
20. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J 1993; 307: 349-353.
21. European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1203-1207.
22. Bobbio M, Bergerone S, Maggioni AP, Malacrida R, Franzosi MG, Barlera S, Tognoni G. Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: the GISSI-3 database. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Am Heart J 1998; 135: 443-448.
23. Newby K. Clinical outcomes according to time to treatment. Clin Cardiol 1997; 20 (11 Suppl 3): III 1-5.
24. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775.
25. Thiemann DR, Coresh J, Oetgen WJ, Powe NR. The association between hospital volume and survival after acute myocardial infarction in elderly patients. N Engl J Med 1999; 340: 1640-1648.
26. Maggioni AP, Maseri A, Fresco C, Franzosi MG, Mauri F, Santoro E, Tognoni G, on behalf of the Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). Age-related increase in mortality among patients with first myocardial infarction treated with thrombolysis. N Engl J Med 1993; 329: 1442-1448.
27. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anti-streplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
28. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
29. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F and Suryapranata H on behalf of the PRAGUE Study Group Investigators. Multicentre randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. Eur Heart J 2000; 21: 823-831.
30. Luepker RV, Raczynski JM, Osganian S, Goldberg RJ, Finnegan JR, Hedges JR, Goff DC Jr, Eisenberg MS, Zapka JG, Feldman HA, Labarthe DR, McGovern PG, Cornell CE, Proschan MA, Simons-Morton DG, for the REACT Study Group. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease. The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA 2000; 284: 60-67.
31. Soumerai SB, McLaughlin TJ, Gurwitz JH, Guadagnoli E, Hauptman PJ, Borbas C, Morris N, McLaughlin B, Gao X, Willinson DJ, Asinger R, Gobel F. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 1998; 279: 1358-1363.
32. Gaspoz JM, Unger PF, Urban P, Chevrolet JC, Rutishauser W, Lovis C, Goldman L, Heliot C, Sechaud L, Mischler S, Waldvogel FA. Impact of a public campaign on pre-hospital delay in patients reporting chest pain. Heart 1996; 76: 150-155.
33. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. Prehospital-initiated vs. hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211-1216.
34. Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23: 1-5.
35. European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383-389.
36. Task Force of the European Society of Cardiology and the European Resuscitation Council. The pre-hospital management of acute heart attacks. Recommendations of the task force. Eur Heart J 1998; 19: 1140-1164.
37. Rawles J, Sinclair C, Jennings K, Ritchie L, Waugh N. Audit of prehospital thrombolysis by general practitioners in peripheral practices in Grampian. Heart 1998; 80: 231-234.
38. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
39. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-2732.
40. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, Topol EJ, Califf RM. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999; 100: 14-20.
41. Jhangiani AH, Jorgensen MB, Kotlewski A, Mansukhani PW, Aharonian VJ, Mahrer PR. Community practice of primary angioplasty for myocardial infarction. Am J Cardiol 1997; 80: 209-212.
42. Danchin N, Vaur L, Genes N, Etienne S, Angioi M, Ferrières J, Cambou JP. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. Circulation 1999; 99: 2639-2644.
43. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, Moreyra E, Traboulsi M, Racine N, Riba AL, Thompson MA, Rorhrbeck S, Lundergan CF, for the PACT Investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT Trial. J Am Coll Cardiol 1999; 34: 1954-1962.
44. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S, the Israeli SPRINT Investigators. In-hospital and 1-year mortality in 1524 women after myocardial infarction. Comparison with 4315 men. Circulation 1991; 83: 484-491.
45. Lincoff AM, Califf RM, Ellis SG, Sigmon KN, Lee KL, Leimberger JD, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? J Am Coll Cardiol 1993; 22: 1780-1787.
46. White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, for the Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation 1993; 88: 2097-2103.
47. Maynard C, Litwin PE, Martin JS, Weaver WD. Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med 1992-152: 972-976.
48. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-85.